↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (2004). „Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors”. Eur. J. Pharmacol.495 (2–3): 97–102. DOI:10.1016/j.ejphar.2004.05.033. PMID15249157.
↑Lovell PJ, Bromidge SM, Dabbs S, et al. (2000). „A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970)”. J. Med. Chem.43 (3): 342–5. DOI:10.1021/jm991151j. PMID10669560.
↑Foong JP, Bornstein JC. (2009). „5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig”. Neuroreport.20 (3): 325–330. DOI:10.1097/WNR.0b013e3283232caa. PMID19190523.